HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and
HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. is building a pathway to long-term future growth on a strong foundation of capabilities. The innovation-focused pharmaceuticals manufacturer is well positioned to adapt to the swiftly changing global market and emerging opportunities in health care. According to Alok Sonig, chief executive officer for developed markets, Dr. Reddy’s is
HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories plans to buy eight Abbreviated New Drug Applications (ANDAs) in the United States from Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc for $350 million in cash. Dr. Reddy’s, which announced the agreement over the weekend, said the acquired products are being divested by
HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. has acquired six over-the-counter health product brands from Ducere Pharma LLC. Financial terms of the agreement weren’t disclosed. India-based Dr. Reddy’s, which has its U.S. office in Princeton, N.J., said the deal brings the company into the consumer health care arena. The brands being acquired from New Hope,
